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Abstract: 
 
Aim: (5Z)-7-Oxozeaenol was studied to reveal the path through which it exerts its effects on 
triple-negative MDA-MB-231 breast cancer cells. Materials and Methods: The apoptotic effect 
of (5Z)-7-oxozeaenol on MDA-MB-231 cancer cells was analyzed by cell flow cytometry. The 
effects of (5Z)-7-oxozeaenol on the expression of the nuclear factor kappa B (NF-κB) p65, p50, 
IκB kinase (IKKα), IKKβ and caspase-7 were analyzed by western blot. The expression of 
intracellular reactive oxygen species (ROS) and effects on cell adhesion were also assessed. Cell 
viability was determined using the 3[4,5-dimethylthiazol-2-yl-]2,5-diphenyl tetrazolium bromide 
(MTT) assay. Results: (5Z)-7-Oxozeaenol down-regulated NF-κB in a dose-dependent manner. 
Intracellular levels of ROS increased in a dose-dependent manner when treated with (5Z)-7-
oxozeaenol and potentiated in the presence of H2O2, when compared to paclitaxel which was 
used as positive control. Treatment with (5Z)-7-oxozeaenol resulted in G1-phase arrest of treated 
cells and inhibition of cell proliferation. Cell adhesion was notably affected in treated cells. (5Z)-
7-Oxozeaenol also significantly enhanced apoptosis of treated cells, through the activation of 
caspase-7. Conclusion: Our findings suggest that (5Z)-7-oxozeaenol is a potent up-stream 
inhibitor of the NF-κB pathway, enhances the sensitivity of treated cells to apoptosis induced by 
ROS, and affects cell adhesion of MDA-MB-231 breast cancer cells. Thus, (5Z)-7-oxozeaenol is 
a potential new lead for breast cancer drug development since it might, in combination therapy, 
enhance the efficacy of current treatments and reduce resistance to chemotherapy of triple 
negative breast cancer. 
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Abstract. Aim: (5Z)-7-Oxozeaenol was studied to reveal the
path through which it exerts its effects on triple-negative MDA-
MB-231 breast cancer cells. Materials and Methods: The
apoptotic effect of (5Z)-7-oxozeaenol on MDA-MB-231 cancer
cells was analyzed by cell flow cytometry. The effects of (5Z)-
7-oxozeaenol on the expression of the nuclear factor kappa B
(NF-κB) p65, p50, IκB kinase (IKKα), IKKβ and caspase-7
were analyzed by western blot. The expression of intracellular
reactive oxygen species (ROS) and effects on cell adhesion
were also assessed. Cell viability was determined using the
3[4,5-dimethylthiazol-2-yl-]2,5-diphenyl tetrazolium bromide
(MTT) assay. Results: (5Z)-7-Oxozeaenol down-regulated NF-
κB in a dose-dependent manner. Intracellular levels of ROS
increased in a dose-dependent manner when treated with (5Z)-
7-oxozeaenol and potentiated in the presence of H2O2, when
compared to paclitaxel which was used as positive control.
Treatment with (5Z)-7-oxozeaenol resulted in G1-phase arrest
of treated cells and inhibition of cell proliferation. Cell
adhesion was notably affected in treated cells. (5Z)-7-
Oxozeaenol also significantly enhanced apoptosis of treated
cells, through the activation of caspase-7. Conclusion: Our
findings suggest that (5Z)-7-oxozeaenol is a potent up-stream
inhibitor of the NF-κB pathway, enhances the sensitivity of
treated cells to apoptosis induced by ROS, and affects cell
adhesion of MDA-MB-231 breast cancer cells. Thus, (5Z)-7-
oxozeaenol is a potential new lead for breast cancer drug
development since it might, in combination therapy, enhance
the efficacy of current treatments and reduce resistance to
chemotherapy of triple negative breast cancer.
The triple-negative breast cancer cells, MDA-MB-231, are
hormone independent and lack receptors for estrogen (ER),
progesterone (PgR), and the human epidermal growth factor
2 (HER-2) (1). MDA-MB-231 cells are also deficient in p53
suppressor gene (2). The cells are aggressive, metastatic and
do not respond to existing pharmacological treatments, such
as herceptin and estrogen antagonists, and there is still need
for more effective targeted treatment of malignancies caused
by this type of cell (3). Thirty-five out of the 60 NF-κB-
related genes are up-regulated in inflammatory breast cancer,
which are related to apoptosis, immune response,
proliferation, tumor promotion, and angiogenesis (4). Since
the nuclear factor kappa B (NF-κB) cell signaling pathway
is responsible for survival signaling, proliferative control,
and promotes resistance to certain tumorigenic agents and
chemotherapy (4), targeting NF-κB activity and inducing
apoptosis might result in a promising approach to the
development of more effective antineoplastic agents. 
Our group has reported that the resorcylic acid lactone (5Z)-
7-oxozeaenol affected cervical HeLa cells through caspase-3-
induced cell death (5). It has also previously been shown by
Ninomiya-Tsuji and co-workers that (5Z)-7-oxozeaenol
inhibits the transforming growth factor β-activated kinase 1
(TAK1), a member of the mitogen-activated kinase
(MAPKKK) family, likely by competitive binding at the ATP
binding site (6). A closely related analog of (5Z)-7-oxozeaenol
(termed: E6201) is currently in phase II clinical trials for the
treatment of melanoma, by Eisai Inc. (7, 8) as well as a
possible topical agent for psoriasis (9). In this study, it has
been examined the apoptotic effects of (5Z)-7-oxozeaenol
(Figure 1) (10) on triple-negative breast cancer cells and the
inhibitory effects of this compound on the NF-κB pathway and
on cell adhesion. 
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Materials and Methods
Reagent sources. (5Z)-7-Oxozeaenol was previously isolated from
a filamentous fungus as part of our drug discovery program (10).
Vitamin C, iron sulfate (FeSO4), hydrogen peroxide (H2O2),
propidium iodine (PI), 3[4,5-dimethylthiazol-2-yl-]2,5-diphenyl
tetrazolium bromide (MTT), and 2’,7’-dichlorfluorescein-diacetate
(DCFH-DA) were purchased from Sigma Aldrich (St. Louis, MO,
USA). Rocaglamide was acquired from Enzo Life Sciences, Inc.
(Farmingdale, NY, USA).
Cell culture. Human breast cancer cell line (MDA-MB-231) was
obtained from the American Type Culture Collection, Manassas, VA,
USA. These cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine calf serum and 10%
antibiotic-antimycotic from Gibco (Rockville, MD, USA). The cells
were kept at 37˚C and in an atmosphere with 5% CO2. 
Cytotoxicity assay. The cytotoxicity of (5Z)-7-oxozeaenol and the
cell viability was assessed using 3[4,5-dimethylthiazol-2-yl-]2,5-
diphenyl tetrazolium bromide (MTT) assay. Cells were seeded in
96-well plates and treated with (5Z)-7-oxozeaenol at various
concentrations. Optical density at 570 nm and detection of formazan
was a measure of cell viability. Cell survival was calculated based
on non-treated cells that were used as negative control. The
concentration at which 50% of the cell growth was inhibited (IC50)
was calculated. Paclitaxel was used as the positive control.
Immunoblotting. The experiments were performed following a
previously described procedure (5). To confirm the effects of (5Z)-7-
oxozeaenol on the NF-κB pathway, MDA-MB-231 cells were treated
at different concentrations (0.008, 0.016, 0.4, 2.0 and 10 mM) for 24
h. Cells were also treated with rocaglamide as a positive control.
Briefly, cells were lysed using PhosphoSafe Lysis Buffer (Novagen,
Madison, WI, USA). Protein concentration of the cell lysate was
determined by using Bradford protein assay kit and albumin standard
(Thermo Scientific, Rockford, IL, USA). Absorbance of cell extract
samples and of albumin standard dilutions was measured using
Fluostar Optima plate reader (BMG Labtech Inc., Durham, NC,
USA). Equal amounts of protein (20 ug) were loaded together with
lithium dodecyl sulfate (LDS) sample loading buffer (Invitrogen,
Carlsbad, CA, USA) and determined using Nu-PAGE 10% sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) Bis-
Tris gels together with SeeBlue® Plus2 Pre-Stained Standard Ladder
(Invitrogen). Electrophoresis was accomplished using SDS-PAGE
running buffer in a Nu-PAGE XCell SureLock Module from
Invitrogen. Proteins were transferred from the gel to a polyvinyldiene
fluoride (PVDF) membrane using tris buffered saline with tween-20
buffer (TBS-T). The blots were then blocked at room temperature
using non-fat milk and subsequently probed with primary antibodies
(1:1000) against each target protein using 1% bovine serum albumin
(BSA) in TBS-T overnight. Primary antibodies to caspase-7, NF-κB
p65 (65 kDa) and p50 (50 kDa), IκB kinase (IKKα), and IKKβ were
obtained from Cell Signaling Technologies (Beverly, MA, USA). The
secondary horseradish peroxidase (HRP) conjugated antibodies
(1:2000) were purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA). Conjugated antibodies were detected using
Chemiluminescent Substrate Supersignal Femto LumiGLO kit
(Thermo Scientific, Rockford, IL, USA).
ROS assay. The assay was performed following a previously described
protocol (5, 11). The presence of ROS in treated cells, in the absence
and presence of H2O2, was detected using the fluorescent probe 2’,7’-
dichlorfluorescein-diacetate (DCFH-DA) (Sigma Aldrich, St. Louis,
MO, USA). Cells were seeded in a 96-well plate and treated with (5Z)-
7-oxozeaenol (0.28 μM-280 μM) or controls for 5 h. Cells were then
either treated or not-treated with H2O2 (1.25 mM) and FeSO4 (0.2
mM), followed by incubation for 30 minutes. In these experiments,
vitamin C and H2O2 were used as controls. Afterwards, the fluorescent
probe DCFH-DA was added to detect intracellular ROS. Fluorescence
was detected and measured using FLUOstar Optima fluorescence plate
reader (BMG Labtechnologies GmbH, Inc., Durham, NC, USA) with
an excitation wavelength of 485 nm and emission wavelength of 530
nm. All treatments were performed in triplicate and are representative
of at least two different experiments. 
Cell cycle analysis. Cell death and apoptosis were determined by
using propidium iodine (PI) to stain DNA in MDA-MB-231 cells.
The MDA-MB-231 cells were seeded on 10 cm plates and treated
with (5Z)-7-oxozeaenol (10 μM) for 24 h. Treated and not-treated
cells were then washed with phosphate buffered saline (PBS),
treated with trypsin EDTA, centrifuged, and re-suspended in PBS.
Afterwards, cells were fixed using ethanol (70%), kept on ice for 1
h, washed, re-suspended in ice-cold PBS, and treated with RNAase
(20 mg/ml), followed by 1 h incubation at 37˚C. Cells were stained
with PI (1.0 mg/ml) (Sigma-Aldrich, St. Louis, MO, USA) and kept
in the dark until analysis using BD FACS Canto II (San Jose, CA,
USA) at 488 nm (5). Comparison of the results from both treated
and not-treated cells is presented below.
Cell adhesion assay. Cell suspension was plated in a 96-well plate,
and treated in triplicates with different concentrations of (5Z)-7-
oxozeaenol for 5 h. Cells were then washed with PBS, trypsinated
and re-suspended in cell media. Cells were counted using a
hemocytometer and an inverted microscope (Axiovert 40 CFL,
Zeiss). Cell adhesion was calculated based on non-treated cells that
were used as negative control.
Results
Cytotoxicity. (5Z)-7-Oxozeaenol was found to significantly
inhibit the growth and cell viability of triple negative MDA-MB-
231 breast cancer cells as determined by the MTT reduction
assay (Figure 2). To understand the mechanism of growth
inhibition, further analysis was conducted as presented below. 
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Figure 1. Chemical structure of (5Z)-7-oxozeaenol (10).
Western blot analysis. (5Z)-7-Oxozeaenol was identified
previously as being able to inhibit NF-κB in cervical HeLa
cells (5, 11). In this study, (5Z)-7-Oxozeaenol exhibited
inhibitory effects on mediators of the NF-κB pathway, and
more specifically on p65 (65 kDa) and p50 (50 kDa), in a
concentration dependent manner in MDA-MB-231 treated
cells (Figure 3). Likewise, the expression levels of up-stream
mediators of the NF-κB pathway, IKKα and -β, were down-
regulated in a concentration-dependent manner (Figure 4).
Western blot analysis also showed that cell death might be
induced by a caspase-7-dependent pathway in MDA-MB-231
cells (Figure 5).
ROS assay. This assay was performed on MDA-MB-231
cells in absence and presence of H2O2/FeSO4, respectively
(Figure 6). The intracellular levels of ROS increased in a
concentration dependent manner when cells were treated
with (5Z)-7-oxozeaenol alone. The levels of ROS were
further potentiated when cells were treated with (5Z)-7-
oxozeaenol in the presence of H2O2. Vitamin C and H2O2
were used as controls. The up-regulation of ROS was
indicative of the oxidative stress induced by (5Z)-7-
oxozeaenol in MDA-MB-231-treated cells. 
Cell cycle analysis. A total of 37% of untreated MDA-MB-
231 were found to be in the G1-phase compared to 64% of
treated cells (Figure 7). Accumulation of MDA-MB-231 cells
in the G1-phase after treatment was observed by cell flow
cytometry. Thus, (5Z)-7-oxozeaenol induced cell death
through arrest of MDA-MB-231 treated cells in the G1-phase. 
Cell adhesion. Cell adhesion was affected in treated cells
when compared to untreated MDA-MB-231 breast cancer
cells (Figures 8 and 9). After 5 h of treatment with (5Z)-7-
oxozeaenol (0.28 μM), 78% of treated cells were detached.
Untreated cells were attached (100%) to the wells after 5 h
of incubation under the same conditions as the treated cells.
Discussion
Induction of the transcription factor NF-κB prevents cancer
cells from entering apoptosis (12). Both IKKβ and NF-κB in
the canonical pathway are induced by the pro-inflammatory
cytokinines (IL-1), tumor necrosis factor-α (TNF-α), and
epidermal growth factor (EGF), as well as free radicals (13).
NF-κB is sequestered in the cytoplasm, bound to IκB. After
phosphorylation of IκB by the IκB kinase (IKK), NF-κB is
subsequently released and translocated to the nucleus, where it
exerts its effects, activating a wide range of target genes that
are involved in apoptosis inhibition, cell adhesion, and cell
signaling mediators (14). Inhibition by (5Z)-7-oxozeaenol
would likely affect the ubiquitination of the NF-κB complex
and the subsequent proteasome degradation of the transcription
element. Additionally, inadequate NF-κB regulation has been
linked to cancer, inflammation, and autoimmune diseases.
Inflammatory breast cancer is frequently hormone receptor-
negative and more aggressive than other types of cancer (4),
making NF-κB an attractive target for the discovery of new
NF-κB inhibitors as potential cancer chemotherapeutic agents
for the treatment of triple negative breast cancer. 
In previous studies, (5Z)-7-oxozeaenol was biologically
evaluated in different types of cells, but to our knowledge, there
is no previous report on the study of this compound using
hormone independent MDA-MB-231 breast cancer cells. Since
(5Z)-7-oxozeaenol exhibited a strong cytotoxic effect on this
type of cell (Figure 2), attempts are being made to uncover the
potential path through which this compound induces cell death
in hormone-independent cancer cells. For this study, it is
hypothesized that (5Z)-7-oxozeaenol is an NF-κB inhibitor that
induces apoptosis through the caspase-7-mediated pathway and
reduces cell adhesion of MDA-MB-231 hormone-independent
breast cancer cells. As an NF-κB inhibitor, (5Z)-7-oxozeaenol
treatment did not inhibit K-RAS activity induced by EGF (5),
suggesting that the NF-κB pathway was affected by (5Z)-7-
oxozeaenol through a different avenue. The effect of (5Z)-7-
Munoz Acuna et al: Effects of (5Z)-7-Oxozeaenol on Breast Cancer Cells
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Figure 2. Cell viability was assessed using the 3[4,5-dimethylthiazol-2-yl-]2,5-diphenyl tetrazolium bromide (MTT) assay. Reduction of cell
proliferation was observed in cells treated with increasing concentrations of (5Z)-7-oxozeaenol.
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Figure 3. Western blot analysis was performed on MDA-MB-231 cellular extracts and showed that (5Z)-7-oxozeaenol suppresses NFκB-p65 (65
kDa) and -p50 (50 kDa) activation. The NFκB response was dose dependent. 
Figure 4. IκB kinase α (IKKα) and IκB kinase β (IKKβ) were down-regulated in (5Z)-7-oxozeaenol treated MDA-MB-231 cells. β-Actin was used
as an internal control to establish equivalent loading.
Figure 5. MDA-MB-231 cells treated with (5Z)-7-oxozeaenol expressed caspase-7 in a dose- dependent manner. 
oxozeaenol (0.25 μM) (10) on TNFα induced NF-κB in MDA-
MB-231 cells was analyzed and confirmed by western blot
analysis (Figure 3). The data presented suggests that (5Z)-7-
oxozeaenol inhibits IKKβ/NF-κB by targeting upstream
signaling mediators (Figure 4). Hence, (5Z)-7-oxozeaenol
targets the NF-κB canonical pathway (7, 15) by inhibiting
TNFα induced NF-κB activation (8, 16). TNFα plays a crucial
role in NF-κB activation as well as in inflammatory response
(13). It is also a key element in inflammatory breast cancer
since it is hormone receptor-negative. ROS levels (Figure 6)
were also increased in a dose-dependent fashion, suggesting
that apoptosis might be mediated by high intracellular levels of
ROS (17). Accordingly, inducing oxidative stress in MDA-MB-
Munoz Acuna et al: Effects of (5Z)-7-Oxozeaenol on Breast Cancer Cells
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Figure 6. General evaluation of intracellular reactive oxygen species
(ROS) induction by (5Z)-7-oxozeaenol on MDA-MB-231 cells in the
absence (A) and presence (B) of peroxide (H2O2). Cells were treated at
four different concentrations for 5 h. ROS was detected with fluorescent
probe 2’,7’-dichlorfluorescein-diacetate (DCFH-DA) at 485 nm emission
wavelength and 530 nm excitation wavelength. H2O2 and vitamin C were
used as positive and negative controls, respectively. Each experiment was
carried out in triplicate and the graph represents the results of two
separate experiments. Values represent the means of fluorescent units
(FU) ± SEM of triplicate samples from two independent experiments.
Figure 7. DNA histogram for MDA-MB-231 cells. A: Control exhibited 37%
of MDA-MB-231 cells in G1-phase. B: Treatment with (5Z)-7-oxozeaenol
induced cells cycle arrest in the G1-phase of 64% of MDA-MB-231 cells. 
231 cells appears to affect, as well as it does the activation of
NF-κB p50 and p65. Further, the expression of intracellular
levels of ROS was potentiated when the (5Z)-7-oxozeaenol
treated cells were concomitantly treated with H2O2, suggesting
the potential use of (5Z)-7-oxozeaenol in combination therapy
with other chemotherapeutic drugs that induce ROS
expression in cytotoxic pathways for the treatment of triple
negative breast cancer.
The high level of cytotoxicity exhibited by (5Z)-7-
oxozeaenol also prompted analysis on how the cell cycle was
being affected by this compound. The flow cytometric study
performed using (5Z)-7-oxozeaenol (Figure 7) showed that
this compound block the G1-phase of MDA-MB-231 cells,
thus affecting the metabolic changes that prepare cells for
division. Since NF-κB is also involved in cell adhesion, a
basic analysis of the cell treatment with (5Z)-7-oxozeaenol
after 5 h of incubation confirmed that this compound caused
detachment of 78% of cells from the plates at 0.28 μM
(Figure 8), suggesting that inhibition of NF-κB did reduce
the adhesion of MDA-MB-231 treated cells (Figure 9). Cell
adhesion is important for cell division and survival. Down-
stream factors correlated to NF-κB regulation include effects
on apoptosis regulators, growth factors, receptors, cell
adhesion, and on other members of the RelA/NF-κB family.
Treatment with (5Z)-7-oxozeaenol inhibits the NF-κB
pathway and cell proliferation, and negatively affects cell
adhesion of MDA-MB-231 cells, thus strongly suggesting
that the cell cycle might be interrupted by the effect of this
compound on the NF-κB pathway. The MDA-MB-231 cell
line is a highly invasive and metastatic cell line, thus the
inhibitory effect of (5Z)-7-oxozeaenol on NF-κB and the
effect on cell adhesion might reduce the metastatic
progression of the disease. Therefore, (5Z)-7-oxozeaenol and
related analogs might represent new lead structures in the
treatment of hormone-resistant breast cancer. 
In a previous report, (5Z)-7-oxozeaenol exhibited a dose-
dependent effect on caspase-3 in both an enzyme assay and on
western blot analysis when using cervical HeLa cells (5). In
this study, (5Z)-7-oxozeaenol exhibited a dose-dependent effect
on caspase-7 (Figure 5). Caspase-7 expression was induced
with increasing level of (5Z)-7-oxozeaenol, suggesting that
apoptosis was mediated by the caspase-dependent pathway in
MDA-MB-231 treated cells. These results are in agreement
with a previous report (5). Findings further suggest that (5Z)-7-
oxozeaenol increased the level of intracellular ROS and
activated a caspase-mediated pathway which resulted in G1 cell
cycle arrest. In summary, an antiproliferative effect of (5Z)-7-
oxozeaenol was detected in triple negative MDA-MB-231
breast cancer cells. Thus, NF-κB inhibitory agents, such as
ANTICANCER RESEARCH 32: 2415-2422 (2012)
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Figure 9. Representative images of cellular adhesion of MDA-MB-231
cells using an inverted microscope (Axiovert 40 CFL, Zeiss) and ×20
magnification. A: Representative image of reduced cellular adhesion
of MDA-MB-231 cells after 5 h of treatment with (5Z)-7-oxozeaenol
(280 μM). B: Representative image of cellular adhesion of untreated
MDA-MB-231 cells after 5 h of incubation.
Figure 8. Effect of (5Z)-7-oxozeaenol on the adhesion of MDA-MB-231
breast cancer cells. After 5 h of treatment, 78% of treated cells were
detached from the plates.
(5Z)-7-oxozeaenol, are potential new anti-tumorigenic lead
compounds for the treatment of triple negative breast cancer
since it down-regulates and suppresses the canonical NF-κB
survival pathway in triple negative breast cancer cells and
induces cell-death by ROS accumulation. 
Conclusion
(5Z)-7-Oxozeaenol inhibits NF-κB, increases ROS levels as
well as potentiates ROS expression in the presence of other
ROS inducing agent, and reduces cell adhesion, leading to
cell death by a caspase-mediated pathway. Thus, (5Z)-7-
oxozeaenol, which has been found to inhibit NF-κB activity,
potentiate ROS effect, and exert antiproliferative activity on
MBA-MD-231 breast cancer cells, represents a potential
chemotherapeutic agent that in combination with ROS
inducing anticancer drugs might increase the efficacy of
existing treatments and reduce the incidence of resistance to
chemotherapy in the treatment of inflammatory breast
cancer, particularly triple negative breast cancer.
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